---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-117204"
form_type: "8-K"
ticker: "GRDX"
cik: "0001604191"
company_name: "GridAI Technologies Corp."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:56:04.519411+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Entero Therapeutics to reverse-merge with Journey Therapeutics, issuing 99% equity

## Summary
- Entero (ENTO) signs binding term sheet to acquire all Journey equity; Journey holders get 99% of combined company.
- Post-close, Journey CEO Henry Ji to become CEO and Chairman of the combined company.
- Conditions include $5M equity financing, S-4 effectiveness, Nasdaq listing, and ENTO stockholder approval.
- Combined entity will focus on Journey's NIC platform for oncology and Entero's GI pipeline (latiglutenase, adrulipase, capeserod).
- NIC platform licensed from Mayo Clinic; early Phase 1 data in ovarian/endometrial cancer and non-Hodgkin's lymphoma.

## SEC filing metadata
- accession: 0001104659-24-117204
- form_type: 8-K
- ticker: GRDX
- cik: 0001604191
- company_name: GridAI Technologies Corp.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604191/000110465924117204/0001104659-24-117204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604191/000110465924117204/tm2428268d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-117204
- JSON: https://secwatch.observer/filing/0001104659-24-117204.json
- Plain text: https://secwatch.observer/filing/0001104659-24-117204.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.